[{"id":"c121533e-47d9-4ac4-9593-e7db6d83a51b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06970132","created_at":"2025-09-07T01:34:43.364Z","updated_at":"2025-09-07T01:34:43.364Z","phase":"Phase 1/2","brief_title":"Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation","source_id_and_acronym":"NCT06970132","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e conteltinib (SY-707) • SY-5933"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-05-14"},{"id":"bbff33d0-fbb7-447e-b61a-196b5c2984ea","acronym":"ALTA-3","url":"https://clinicaltrials.gov/study/NCT03596866","created_at":"2021-01-18T17:41:06.342Z","updated_at":"2025-02-25T14:07:13.042Z","phase":"Phase 3","brief_title":"A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT03596866 - ALTA-3","lead_sponsor":"Takeda","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Alecensa (alectinib) • Alunbrig (brigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 248","initiation":"Initiation: 04/19/2019","start_date":" 04/19/2019","primary_txt":" Primary completion: 02/27/2024","primary_completion_date":" 02/27/2024","study_txt":" Completion: 09/12/2024","study_completion_date":" 09/12/2024","last_update_posted":"2025-02-19"},{"id":"3a78f5b1-8ba2-481a-a8fe-73c711e0e9a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03375242","created_at":"2021-01-18T16:39:27.774Z","updated_at":"2025-02-25T14:39:49.048Z","phase":"","brief_title":"Safety and Efficacy of Xalkori ROS1","source_id_and_acronym":"NCT03375242","lead_sponsor":"Pfizer","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 positive","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/25/2017","start_date":" 10/25/2017","primary_txt":" Primary completion: 08/24/2026","primary_completion_date":" 08/24/2026","study_txt":" Completion: 08/24/2026","study_completion_date":" 08/24/2026","last_update_posted":"2025-02-14"},{"id":"52814cd1-a8ab-4fbc-9958-b65faef07451","acronym":"","url":"https://clinicaltrials.gov/study/NCT05599412","created_at":"2022-10-31T13:56:49.808Z","updated_at":"2025-02-25T14:41:38.018Z","phase":"","brief_title":"Post Marketing Surveillance(PMS) Study of Lorviqua in Korea","source_id_and_acronym":"NCT05599412","lead_sponsor":"Pfizer","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/22/2023","start_date":" 05/22/2023","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2025-02-14"},{"id":"a1cc20b7-e120-4c96-ad2e-1583010cd20c","acronym":"CARE study","url":"https://clinicaltrials.gov/study/NCT04094610","created_at":"2021-01-18T20:02:04.781Z","updated_at":"2025-02-25T14:40:19.057Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations","source_id_and_acronym":"NCT04094610 - CARE study","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion • ROS1 fusion • NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-14"},{"id":"4b1b80e8-bcd8-4a78-8ae1-fe238c0362b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126916","created_at":"2021-01-18T15:24:54.957Z","updated_at":"2025-02-25T15:10:35.328Z","phase":"Phase 3","brief_title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","source_id_and_acronym":"NCT03126916","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 724","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"63139aa8-19bf-4602-a810-5c7110a10962","acronym":"","url":"https://clinicaltrials.gov/study/NCT04423185","created_at":"2021-01-18T21:18:39.174Z","updated_at":"2025-02-25T15:26:22.079Z","phase":"Phase 2","brief_title":"PLATFORM Study of Precision Medicine for Rare Tumors","source_id_and_acronym":"NCT04423185","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification","tags":["EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 770","initiation":"Initiation: 08/15/2020","start_date":" 08/15/2020","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-11"},{"id":"277136d1-0119-42be-9629-e04f1cfca67d","acronym":"TRIDENT-1","url":"https://clinicaltrials.gov/study/NCT03093116","created_at":"2021-01-17T17:11:31.349Z","updated_at":"2025-02-25T16:31:09.380Z","phase":"Phase 1/2","brief_title":"A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements","source_id_and_acronym":"NCT03093116 - TRIDENT-1","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ROS1 fusion","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib) • midazolam hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 03/07/2017","start_date":" 03/07/2017","primary_txt":" Primary completion: 02/29/2028","primary_completion_date":" 02/29/2028","study_txt":" Completion: 02/29/2028","study_completion_date":" 02/29/2028","last_update_posted":"2025-02-07"},{"id":"458cb283-b41f-46c8-9cf0-1513a2f0ecd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01828112","created_at":"2021-01-17T17:22:24.644Z","updated_at":"2025-02-25T16:36:14.568Z","phase":"Phase 3","brief_title":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib","source_id_and_acronym":"NCT01828112","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • docetaxel • Zykadia (ceritinib) • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 231","initiation":"Initiation: 06/28/2013","start_date":" 06/28/2013","primary_txt":" Primary completion: 01/26/2016","primary_completion_date":" 01/26/2016","study_txt":" Completion: 11/10/2023","study_completion_date":" 11/10/2023","last_update_posted":"2025-02-07"},{"id":"a0f41c59-aa55-45a8-ab7a-26f77921a6a6","acronym":"GO42286","url":"https://clinicaltrials.gov/study/NCT04774718","created_at":"2021-03-01T14:52:34.144Z","updated_at":"2025-02-25T16:45:19.897Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors","source_id_and_acronym":"NCT04774718 - GO42286","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ALK","pipe":" | ","alterations":" ALK fusion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alecensa (alectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 02/28/2028","primary_completion_date":" 02/28/2028","study_txt":" Completion: 02/28/2032","study_completion_date":" 02/28/2032","last_update_posted":"2025-02-05"},{"id":"e6ddbe9a-bb3f-4f95-a33c-1e9db3a4644c","acronym":"ALINA","url":"https://clinicaltrials.gov/study/NCT03456076","created_at":"2021-01-18T17:02:25.362Z","updated_at":"2025-02-25T16:44:20.606Z","phase":"Phase 3","brief_title":"A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03456076 - ALINA","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Alecensa (alectinib) • pemetrexed • vinorelbine tartrate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 257","initiation":"Initiation: 08/16/2018","start_date":" 08/16/2018","primary_txt":" Primary completion: 06/26/2023","primary_completion_date":" 06/26/2023","study_txt":" Completion: 11/19/2026","study_completion_date":" 11/19/2026","last_update_posted":"2025-02-05"},{"id":"6da256ca-a5e6-48f5-9386-baa4180b20fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03420508","created_at":"2021-01-18T16:52:29.427Z","updated_at":"2025-02-25T16:52:07.457Z","phase":"Phase 2","brief_title":"Treating Patients With Melanoma and ALK Alterations With Ensartinib","source_id_and_acronym":"NCT03420508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK","pipe":" | ","alterations":" BRAF V600 • ALK fusion • ALK mutation","tags":["BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ensacove (ensartinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/10/2018","start_date":" 01/10/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-04"},{"id":"a3255986-c4de-4a9b-bae3-7e5b9fce11d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03611738","created_at":"2021-01-18T17:45:09.767Z","updated_at":"2025-02-25T16:59:48.816Z","phase":"Phase 1","brief_title":"Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC","source_id_and_acronym":"NCT03611738","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Zykadia (ceritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 04/28/2025","primary_completion_date":" 04/28/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-03"},{"id":"bc0153fa-3f27-4593-8ca6-41236ea47eb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03501368","created_at":"2021-01-18T17:13:51.868Z","updated_at":"2025-02-25T15:43:02.794Z","phase":"Phase 1","brief_title":"Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma","source_id_and_acronym":"NCT03501368","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Zykadia (ceritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/27/2018","start_date":" 06/27/2018","primary_txt":" Primary completion: 10/28/2022","primary_completion_date":" 10/28/2022","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-12-04"},{"id":"cec10506-6390-45ed-9785-1b2e4ff57e38","acronym":"QLMA-NSCLC-IIT-001","url":"https://clinicaltrials.gov/study/NCT06697990","created_at":"2025-02-26T13:42:05.793Z","updated_at":"2025-02-26T13:42:05.793Z","phase":"Phase 2","brief_title":"Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients","source_id_and_acronym":"NCT06697990 - QLMA-NSCLC-IIT-001","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" CD8 • IFNG • IL6 • TNFA • CD4 • VCAM1 • CRP","pipe":"","alterations":" ","tags":["CD8 • IFNG • IL6 • TNFA • CD4 • VCAM1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qi Xinke (iruplinalkib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-11-20"},{"id":"002e6ccc-3a81-4cfa-b237-64f0c73db083","acronym":"INTUITT-NF2","url":"https://clinicaltrials.gov/study/NCT04374305","created_at":"2021-01-18T21:07:59.980Z","updated_at":"2025-02-25T14:51:47.217Z","phase":"Phase 2","brief_title":"Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)","source_id_and_acronym":"NCT04374305 - INTUITT-NF2","lead_sponsor":"Scott R. Plotkin, MD, PhD","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib) • Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/20/2020","start_date":" 06/20/2020","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-11-18"},{"id":"f032cb75-7b0a-4fb8-9e69-7cf2c851ab56","acronym":"COMLORLA","url":"https://clinicaltrials.gov/study/NCT06690541","created_at":"2025-02-26T13:54:01.529Z","updated_at":"2025-02-26T13:54:01.529Z","phase":"","brief_title":"Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC","source_id_and_acronym":"NCT06690541 - COMLORLA","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" ALK","pipe":"","alterations":" ","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/10/2024","start_date":" 11/10/2024","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 10/31/2030","study_completion_date":" 10/31/2030","last_update_posted":"2024-11-15"},{"id":"55fca2cd-0dc1-47d8-86f5-df409157addc","acronym":"ALKALINE","url":"https://clinicaltrials.gov/study/NCT04127110","created_at":"2021-01-18T20:09:41.572Z","updated_at":"2025-02-25T12:37:27.279Z","phase":"Phase 2","brief_title":"Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients","source_id_and_acronym":"NCT04127110 - ALKALINE","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lorbrena (lorlatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 11/17/2020","start_date":" 11/17/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2024-11-05"},{"id":"7c4c2c5c-0d9e-41b0-96b2-8600aa7be62a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04318938","created_at":"2021-01-18T20:55:43.511Z","updated_at":"2025-02-25T14:51:44.818Z","phase":"Phase 2","brief_title":"Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping","source_id_and_acronym":"NCT04318938","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" ALK • TP53","pipe":" | ","alterations":" TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation","tags":["ALK • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Alunbrig (brigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 118","initiation":"Initiation: 03/30/2020","start_date":" 03/30/2020","primary_txt":" Primary completion: 01/16/2026","primary_completion_date":" 01/16/2026","study_txt":" Completion: 01/16/2026","study_completion_date":" 01/16/2026","last_update_posted":"2024-10-14"},{"id":"2a11f2ce-d7a1-4499-9adf-7f2d5fda7036","acronym":"ROSALINE","url":"https://clinicaltrials.gov/study/NCT04551495","created_at":"2021-01-18T21:45:49.585Z","updated_at":"2024-07-02T16:34:26.568Z","phase":"Phase 2","brief_title":"Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)","source_id_and_acronym":"NCT04551495 - ROSALINE","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • letrozole • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-06-13"},{"id":"02e83317-1e46-4ec1-8ee3-e88e0be802c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02321501","created_at":"2021-01-18T11:00:33.247Z","updated_at":"2024-07-02T16:34:27.615Z","phase":"Phase 1","brief_title":"Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02321501","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ROS1","pipe":" | ","alterations":" ALK positive • ROS1 rearrangement","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Zykadia (ceritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-10"},{"id":"79853e3c-57e0-4bdc-a5ec-927f20acf680","acronym":"ALKOVE-1","url":"https://clinicaltrials.gov/study/NCT05384626","created_at":"2022-05-20T17:58:30.523Z","updated_at":"2024-07-02T16:34:36.881Z","phase":"Phase 1/2","brief_title":"A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)","source_id_and_acronym":"NCT05384626 - ALKOVE-1","lead_sponsor":"Nuvalent Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • neladalkib (NVL-655)"],"overall_status":"Recruiting","enrollment":" Enrollment 470","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-06-10"},{"id":"149137c3-0ac6-4627-8ec7-485b316d9bc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04322578","created_at":"2021-01-27T19:00:13.739Z","updated_at":"2024-07-02T16:34:58.985Z","phase":"Phase 2","brief_title":"Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC","source_id_and_acronym":"NCT04322578","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Xalkori (crizotinib) • carboplatin • pemetrexed • Orpathys (savolitinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/24/2020","start_date":" 03/24/2020","primary_txt":" Primary completion: 03/24/2025","primary_completion_date":" 03/24/2025","study_txt":" Completion: 03/24/2026","study_completion_date":" 03/24/2026","last_update_posted":"2024-06-04"},{"id":"8a3d3d41-a452-48ff-8178-8d754ba2fbf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05170204","created_at":"2021-12-27T15:54:25.891Z","updated_at":"2024-07-02T16:34:59.196Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05170204","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK fusion • ROS1 fusion","tags":["PD-L1 • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Gavreto (pralsetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 06/17/2029","primary_completion_date":" 06/17/2029","study_txt":" Completion: 04/14/2035","study_completion_date":" 04/14/2035","last_update_posted":"2024-06-04"}]